Abstract
Seventeen equatorial and Southern-Hemisphere countries were studied (Argentina,
Australia, Bolivia, Brazil, Chile, Colombia, Ecuador, Malaysia, New Zealand, Paraguay,
Peru, Philippines, Singapore, South Africa, Suriname, Thailand, Uruguay), which
comprise 9.10 % of worldwide population, 10.3 % of worldwide COVID-19 injections
(vaccination rate of 1.91 injections per person, all ages), virtually every COVID-19
vaccine type and manufacturer, and span 4 continents.
2
In the 17 countries, there is no evidence in all-cause mortality (ACM) by time data of
any beneficial effect of COVID-19 vaccines. There is no association in time between
COVID-19 vaccination and any proportionate reduction in ACM. The opposite occurs.
All 17 countries have transitions to regimes of high ACM, which occur when the
COVID-19 vaccines are deployed and administered. Nine of the 17 countries have no
detectable excess ACM in the period of approximately one year after a pandemic was
declared on 11 March 2020 by the World Health Organization (WHO), until the vaccines
are rolled out (Australia, Malaysia, New Zealand, Paraguay, Philippines, Singapore,
Suriname, Thailand, Uruguay).
Unprecedented peaks in ACM occur in the summer (January-February) of 2022 in the
Southern Hemisphere, and in equatorial-latitude countries, which are synchronous with
or immediately preceded by rapid COVID-19-vaccine-booster-dose rollouts (3rd or 4th
doses). This phenomenon is present in every case with sufficient mortality data (15
countries). Two of the countries studied have insufficient mortality data in January-
February 2022 (Argentina and Suriname).

Posted in

Roli

Leave a Comment

You must be logged in to post a comment.